In 2007, BMS and ImClone amended their codevelopment agreement with Merck KGaA (Merck) to provide for cocommercialization  of  Erbitux  in Japan. The rights under this agreement expire in 2032; however, Lilly has the ability to terminate the agreement after  2018 if it determines that it is commercially unreasonable for Lilly to continue. Erbitux  received marketing approval in Japan in 2008  for the use of  Erbitux  in treating patients with advanced or recurrent colorectal cancer. BMS receives 50% of the pre-tax profit from  Merck sales of   in Japan which is further shared equally with Lilly.  BMS is amortizing $500 million of license acquisition costs in costs of products sold through 2018.  In 2010, BMS and Lilly restructured the EGFR commercialization agreement described above between BMS and ImClone as it relates  to necitumumab, a novel targeted cancer therapy currently in Phase III development for non-small cell lung cancer. Both companies  share in the cost of developing and potentially commercializing necitumumab in the U.S., Canada and Japan. Lilly maintains  exclusive rights to necitumumab in all other markets.  In November 2012, we provided notice of the termination of our global codevelopment and cocommercialization arrangement for  necitumumab (IMC-11F8), a fully human monoclonal antibody being investigated as an anticancer treatment, which was discovered  by ImClone and is part of the alliance between the Company and Lilly, with all rights returning to Lilly. The termination is effective  May 2014, though we and Lilly may terminate earlier.  Summarized financial information related to this alliance is as follows:  BMS acquired Amylin Pharmaceuticals, Inc. (Amylin) on August 8, 2012 (see Note 4 “Acquisitions” for further information). Amylin had previously entered into a settlement and termination agreement with Lilly regarding their collaboration for the global  development and commercialization of  Byetta  and  Bydureon  (exenatide products) under which the parties agreed to transition full  responsibility of these products to Amylin. Although the transition of the U.S. operations was completed, Lilly had not yet transitioned  the non-U.S. operations to Amylin. In September 2012, BMS provided notification to Lilly that BMS will assume essentially all non- U.S. operations of the exenatide products during the first half of 2013 and therefore terminate Lilly’s exclusive right to non-U.S.  commercialization of the exenatide products, subject to certain regulatory and other conditions. BMS is responsible for any non-U.S.  losses incurred by Lilly during 2012 and 2013 up to a maximum of $60 million and is entitled to tiered royalties until the transition is  complete. Promissory notes assumed in the acquisition of Amylin aggregating $1.4 billion were repaid to Lilly during 2012.  BMS and Gilead Sciences, Inc. (Gilead) have a joint venture to develop and commercialize  Atripla  (efavirenz 600 mg/ emtricitabine  200 mg/ tenofovir disoproxil fumarate 300 mg), a once-daily single tablet three-drug regimen for the treatment of human  immunodeficiency virus (HIV) infection, combining  Sustiva , a product of BMS, and  Truvada  (emtricitabine and tenofovir disoproxil  fumarate), a product of Gilead, in the U.S., Canada and Europe. BMS accounts for its participation in the U.S. joint venture under the  equity method of accounting.  Net sales of the bulk efavirenz component of  Atripla  are deferred until the combined product is sold to third-party customers. Net  sales for the efavirenz component are based on the relative ratio of the average respective net selling prices of  Truvada  and  Sustiva .  Summarized financial information related to this alliance is as follows:  Gilead  Year Ended December 31,  Dollars in Millions 2012 2011 2010 Net sales $  702  $   691 $  662  Distribution fees and royalty expense   291   287  275  Research and development expense reimbursement to Lilly - necitumumab   14   12  12  Amortization (income)/expense – upfront, milestone and other licensing payments   38   37  37  Commercialization expense reimbursements to/(from) Lilly   (20)  (18)  (16) Japan commercialization profit sharing (income)/expense, net   (37)  (34)  (39) December 31, Dollars in Millions 2012 2011 Other intangible assets – upfront, milestone and other licensing payments $   211  $  249  Year Ended December 31,  Dollars in Millions 2012 2011 2010 Net sales $  1,267 $   1,204 $  1,053  Equity in net loss of affiliates   (18)   (16)  (12) 40 Bristol-Myers Squibb 